Want to see SE:BIOG.B full AI Analyst Report?
Top Page
BioGaia AB
(BIOG.B)
Select Model
Select Model
Rating:71Outperform
Price Target:
kr138.00
▲(19.48% Upside)
Action:Reiterated
Date:07/20/26
The score is driven primarily by strong financial performance—high margins, strong ROE, and a near debt-free balance sheet—partly offset by slowing growth and weakening recent free cash flow trends. Technicals are mixed with negative MACD despite price holding above longer-term averages, and valuation is a headwind given the high P/E alongside a modest dividend yield.
Positive Factors
High profitability
Sustained high margins indicate structural product-level economics and pricing power in BioGaia's probiotic offerings. Durable gross and operating margins support reinvestment, consistent earnings quality, and resilience to cost swings, enabling long-term cash generation and shareholder returns.
Negative Factors
Slowing revenue growth
The clear deceleration from multi-year growth to near-single-digit then low-single-digit TTM growth signals maturing markets or tougher commercial execution. Persistent top-line slowdown can limit reinvestment capacity, reduce operating leverage benefits, and pressure long-term return expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability
Sustained high margins indicate structural product-level economics and pricing power in BioGaia's probiotic offerings. Durable gross and operating margins support reinvestment, consistent earnings quality, and resilience to cost swings, enabling long-term cash generation and shareholder returns.
Read all positive factors
BioGaia AB (BIOG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr11.12B
Dividend Yield1.49%
Average Volume (3M)150.15K
Price to Earnings (P/E)31.6
Beta (1Y)0.37
Revenue Growth9.78%
EPS Growth21.14%
CountrySE
Employees251
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)3.43
Shares Outstanding98,497,170
10 Day Avg. Volume190,267
30 Day Avg. Volume150,146
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.86
Revenue Forecast (FY)kr1.67B
BioGaia AB Business Overview & Revenue Model
Company Description
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The co...
How the Company Makes Money
BioGaia makes money primarily by commercializing probiotic products and probiotic strains based on its Lactobacillus reuteri technology. A key revenue stream is sales of finished consumer products (e.g., drops, tablets/lozenges, chewables, capsule...
BioGaia AB Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.58B | 1.54B | 1.42B | 1.30B | 1.10B | 785.11M |
| Gross Profit | 1.15B | 1.13B | 1.03B | 950.19M | 801.93M | 582.95M |
| EBITDA | 465.84M | 454.33M | 539.44M | 494.92M | 476.89M | 276.86M |
| Net Income | 347.23M | 332.76M | 351.39M | 365.35M | 373.77M | 196.27M |
Balance Sheet | ||||||
| Total Assets | 1.34B | 1.60B | 2.03B | 2.33B | 2.21B | 2.13B |
| Cash, Cash Equivalents and Short-Term Investments | 446.27M | 801.31M | 1.22B | 1.54B | 1.49B | 1.48B |
| Total Debt | 0.00 | 6.90M | 7.10M | 8.80M | 16.01M | 9.81M |
| Total Liabilities | 235.14M | 283.59M | 310.07M | 305.54M | 241.55M | 250.69M |
| Stockholders Equity | 1.10B | 1.31B | 1.72B | 2.03B | 1.97B | 1.88B |
Cash Flow | ||||||
| Free Cash Flow | 299.67M | 302.97M | 359.06M | 377.25M | 301.03M | 215.50M |
| Operating Cash Flow | 314.80M | 306.57M | 373.22M | 425.96M | 318.94M | 221.88M |
| Investing Cash Flow | -15.28M | -3.34M | -14.07M | -50.94M | -18.14M | -126.97M |
| Financing Cash Flow | -475.92M | -709.87M | -689.72M | -308.42M | -313.59M | -81.85M |
BioGaia AB Technical Analysis
Negative
115.50
Price Trends
115.53
Negative
119.00
Negative
112.12
Negative
Market Momentum
-1.20
Positive
35.36
Neutral
5.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOG.B, the sentiment is Negative. The current price of 115.5 is above the 20-day moving average (MA) of 114.04, below the 50-day MA of 115.53, and above the 200-day MA of 112.12, indicating a bearish trend. The MACD of -1.20 indicates Positive momentum. The RSI at 35.36 is Neutral, neither overbought nor oversold. The STOCH value of 5.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOG.B.
BioGaia AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | kr11.12B | 31.63 | 27.58% | 1.49% | 9.78% | 21.14% | |
66 Neutral | kr7.90B | 31.42 | ― | 0.81% | 9.35% | -91.93% | |
56 Neutral | kr3.43B | 43.40 | 1.16% | 1.29% | 4.84% | 22.61% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr423.36M | -31.27 | ― | ― | 54.37% | 52.22% | |
42 Neutral | kr521.88M | -11.17 | ― | ― | 3.26% | 16.82% |
* General Sector Average
SE:BIOG.B
BioGaia AB
108.50
8.56
8.56%
SE:MVIR
Medivir AB
1.84
-0.04
-2.02%
SE:SECARE
Swedencare AB
21.70
-17.39
-44.48%
SE:APOTEA
Apotea AB
74.15
-21.25
-22.28%
SE:ENZY
Enzymatica AB
2.07
-0.30
-12.66%
SE:CLBIO
Corline Biomedical AB
15.40
0.85
5.84%
BioGaia AB Corporate Events
BioGaia lifts margins on probiotic growth and expands into skincare
Jul 17, 2026
BioGaia AB reported solid growth in the second quarter of 2026, with net sales rising 9% to SEK 440.9 million and operating profit up 22% to SEK 132.1 million, lifting the operating margin to 30%. The Adult Health segment outpaced Pediatrics in gr...
BioGaia Sets July 17 Date for Q2 2026 Earnings and Investor Audiocast
Jul 2, 2026
BioGaia AB will publish its financial report for the second quarter of 2026 on July 17 at 8:00 AM CEST, followed by a live audiocast at 9:30 AM CEST where CEO Theresa Agnew and CFO Alexander Kotsinas will present the results and take questions. Th...
BioGaia Expands Microbiome Skincare Line for Babies and Children
Jun 18, 2026
BioGaia’s subsidiary Biogaia New Sciences AB has broadened the BioGaia Skincare portfolio by adding a Gentle Balm to Milk Wash and a Soothing Face Body Lotion, completing a three-step routine with its existing Probiotic Ointment. The range,...
BioGaia AGM Confirms Dividend, Charitable Grants and New Incentive Plan
May 7, 2026
BioGaia AB’s annual general meeting approved the 2025 financial statements, discharged the board and CEO from liability, and confirmed Deloitte AB as auditor, while maintaining a six-member board with Mauricio Graber re-elected as chairman a...
BioGaia Posts Solid Q1 Growth, Tightens U.S. Grip and Bolsters Probiotic Science
May 7, 2026
BioGaia reported first-quarter 2026 net sales of SEK 372.6 million, up 2% year on year, with underlying growth of 15% when excluding currency effects and an operating margin maintained at 27%. The Pediatrics segment generated SEK 272.2 million and...
BioGaia launches next-generation dual-strain probiotic drops for colicky infants
May 7, 2026
BioGaia AB has introduced BioGaia Protectis Plus, a next-generation, dual-strain probiotic drop formulation for babies with colic and sensitive digestive systems, combining its original L. reuteri Protectis strain with the newly patented L. reuter...
BioGaia Sets May 7 Release and Briefing for Q1 2026 Results
Apr 30, 2026
BioGaia will publish its financial report for the first quarter of 2026 on May 7 at around 8:00 AM CEST, followed by a live audiocast with CEO Theresa Agnew and CFO Alexander Kotsinas at 9:30 AM CEST to present the results and answer questions. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.